ESI Group and the DesCartes Program Aiming at Transforming Singapore Into a Hybrid, Ethical and Sustainable Smart Nation
25.1.2022 10:00:00 EET | Business Wire | Press release
Regulatory News:
ESI Group, Rungis, France, (ISIN Code: FR0004110310, Mnemo: ESI), a global player in virtual prototyping for industries, is collaborating in the launch of the DesCartes project in Singapore by providing its scientists, its expertise in hybridization methods and its virtual prototyping software solutions to the various stakeholders.
DesCartes a 5-year and a 35 million euros budget collaborative program, has been selected by the National Research Foundation (NRF) of Singapore and is based on the CREATE campus, "Campus for research excellence and technological enterprise", the international research hub of Singapore. Behind this very French name lies one of the largest collaborative programs of the CNRS: the "Program on Intelligent Modelling for Decision-making in Critical Urban Systems", dedicated to Hybrid Artificial Intelligence.
A smart city project to a better extent: A smart nation project
For many years, many smart cities projects have been launched. The principle of these smart cities is to collect data generated by sensors, to deploy specific applications, such as sensors indicating air pollution, alerts on accidents, traffic conditions in real time... However, the concept of smart nation carried by Singapore differs from the others because it pushes the concept to its paroxysm: from the digitization of an entity, a building, a single system to the digitization of a whole city interacting in real time.
From electrical grid optimization to delivery drones
DesCartes is developing hybrid AI methods, combining AI with knowledge-based models (physics, engineering), to enable trusted, real-time decision-making that is "people-centric" and "in harmony with society." All in response to complex situations related to critical urban systems in the context of Singapore's "Smart Nation." This research will be applied, for example, to urban mobility or energy management, or to anticipate the needs of future transportation networks, smart industries, or smart buildings. "For example, we aim to develop solutions to optimize the supply and demand of the electricity network, or solutions to improve the flow of cab drones or delivery drones, or to develop intelligent predictive maintenance applied to industrial tools," explains Dominique Baillargeat, director of CNRS@CREATE. Systems in the city that will be able to analyze data on the use of services by the population and then make optimization decisions.
ESI's role in this project.
ESI, recognized worldwide for its predictive physics modeling and virtual prototyping expertise, will play several roles in this program. First, its Scientific Director, also a member of CNRS and ENSAM, Prof. Francisco Chinesta, will be the program director. In addition, the Group will make its performance simulation solutions (VPS, VA One, Simulation X, etc.) and its expertise in hybridization and model reduction methods available to the partners and the program. ESI will thus be able to predict material behavior in real time, anticipate incidents (associated with damage, cracks, corrosion, etc.), model the wind for better use of drones, and make city management more intelligent and human-friendly. Finally, ESI will bring all its engineering expertise to optimize the platform in which the data will be used to make the right decision at the right time.
Dr. Francisco Chinesta, leader of the engineering activity for ESI in this project, says: "The goal of the Singapore program is to think and design an interconnected smart city with features that will revolutionize the concept of smart cities. In this project, it is essential to place the citizen - the human, but also more generally the living - at the heart of the hybridization devices. All the partners in this project aim to make Singapore an ethical, responsible and secure new city."
The Descartes program partners
The Descartes project involves on the French side:
- CNRS
- 13 universities and prestigious schools : Université Paris-Saclay, Université Toulouse Paul Sabatier, Université Lyon III Jean Moulin, Université de Bordeaux, École Nationale de l'Aviation Civile, Université Paris Sciences & Lettres, Université de Strasbourg, Arts et Métiers, INP Grenoble, INP ENSEEIHT, Ecole Normale Supérieure de Paris-Saclay, Université Grenoble-Alpes, Université Côte-d'Azur.
and, on the Singaporean side:
- 3 universities: Nanyang Technology University, National University of Singapore, Singapore University of Technology and Design.
- A*STAR: Agency for Science, Technology and Research. A*STAR is the national R&D agency of Singapore.
It is developed in collaboration with five industrial partners: ARIA, CETIM MATCOR, EDF, ESI Group and Thales.
About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005770/en/
Contact information
ESI - Press & Shareholders
Florence Barré
investors@esi-group.com
+33 1 49 78 28 28
Verbatee – Press & Investors Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
